INOZYME PHARMA INC (INZY) Stock Price & Overview
NASDAQ:INZY • US45790W1080
Current stock price
The current stock price of INZY is 4 USD. Today INZY is up by 0.25%. In the past month the price increased by 0.76%. In the past year, price decreased by -10.91%.
INZY Key Statistics
- Market Cap
- 258.24M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.68
- Dividend Yield
- N/A
INZY Stock Performance
INZY Stock Chart
INZY Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to INZY. When comparing the yearly performance of all stocks, INZY is one of the better performing stocks in the market, outperforming 98.56% of all stocks.
INZY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INZY. INZY has a bad profitability rating. Also its financial health evaluation is rather negative.
INZY Earnings
INZY Forecast & Estimates
13 analysts have analysed INZY and the average price target is 6.85 USD. This implies a price increase of 71.21% is expected in the next year compared to the current price of 4.
INZY Groups
Sector & Classification
INZY Financial Highlights
Over the last trailing twelve months INZY reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -24.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.14% | ||
| ROE | -335.61% | ||
| Debt/Equity | 0.65 |
INZY Ownership
INZY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INZY
Company Profile
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The firm is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The firm also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
Company Info
IPO: 2020-07-24
INOZYME PHARMA INC
321 Summer Street, Suite 400
Boston MASSACHUSETTS 02210 US
CEO: Axel Bolte
Employees: 67
Phone: 18573304340
INOZYME PHARMA INC / INZY FAQ
What does INOZYME PHARMA INC do?
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The firm is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The firm also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
Can you provide the latest stock price for INOZYME PHARMA INC?
The current stock price of INZY is 4 USD. The price increased by 0.25% in the last trading session.
What is the dividend status of INOZYME PHARMA INC?
INZY does not pay a dividend.
What is the ChartMill technical and fundamental rating of INZY stock?
INZY has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for INZY stock?
13 analysts have analysed INZY and the average price target is 6.85 USD. This implies a price increase of 71.21% is expected in the next year compared to the current price of 4.
Can you provide the market cap for INOZYME PHARMA INC?
INOZYME PHARMA INC (INZY) has a market capitalization of 258.24M USD. This makes INZY a Micro Cap stock.